Atoum Manar Fayiz, Al-Khatib Yasmeen Mohammad
Department of Medical Laboratory Sciences, Faculty of Allied Health, Hashemite University, Zarqa 13115, Jordan.
Chin Med J (Engl). 2017 May 5;130(9):1074-1078. doi: 10.4103/0366-6999.204933.
Breast cancer is the most common type of cancer among females. Genetic polymorphisms might have a role in carcinogenesis. The aim of this study was to determine whether C to T base substitution within TaqI Vitamin D receptor (VDR) gene (rs731236) in exon 9 was a risk factor among patients with breast cancer.
Peripheral blood was drawn from 122 Jordanian breast cancer patients and 100 healthy Jordanian volunteers in Al-Basheer Hospital during the summer months (from June to November of 2013, 2014, and 2015). DNA was amplified using polymerase chain reaction (PCR), followed by TaqI restriction enzyme digestion. Quantification of serum 25-hydroxy Vitamin D (25[OH]D) level was determined by competitive immunoassay Elecsys.
Genotypic frequencies for TaqI TT, Tt, and tt genotypes were 41%, 46%, and 13% for breast cancer compared to 42%, 50%, and 8% for control, respectively. Vitamin D serum level was significantly lower in the breast cancer patients (8.1 ± 0.3 ng/ml) compared to the control group (21.2 ± 0.6 ng/ml; P= 0.001). This study showed an inverse association between 25(OH)D serum level and breast cancer risk (odds ratio [OR], 22.72, 95% confidence interval [CI], 10.06-51.29).
An inverse association was found between 25(OH)D serum level and breast cancer risk. Statistical difference was also found between different VDR TaqI genotypes and circulating levels of 25(OH)D among Jordanian females with breast cancer.
乳腺癌是女性中最常见的癌症类型。基因多态性可能在致癌过程中起作用。本研究的目的是确定外显子9中TaqI维生素D受体(VDR)基因(rs731236)的C到T碱基替换是否是乳腺癌患者的危险因素。
在夏季月份(2013年、2014年和2015年的6月至11月),从阿尔-巴希尔医院的122名约旦乳腺癌患者和100名健康约旦志愿者中采集外周血。使用聚合酶链反应(PCR)扩增DNA,随后进行TaqI限制性酶切。采用竞争免疫测定法Elecsys测定血清25-羟基维生素D(25[OH]D)水平。
乳腺癌患者中TaqI TT、Tt和tt基因型的基因型频率分别为41%、46%和13%,而对照组分别为42%、50%和8%。乳腺癌患者的维生素D血清水平(8.1±0.3 ng/ml)显著低于对照组(21.2±0.6 ng/ml;P = 0.001)。本研究显示25(OH)D血清水平与乳腺癌风险呈负相关(优势比[OR]为22.72,95%置信区间[CI]为10.06 - 51.29)。
发现25(OH)D血清水平与乳腺癌风险呈负相关。在约旦乳腺癌女性中,不同的VDR TaqI基因型与25(OH)D的循环水平之间也存在统计学差异。